

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

ALLERGAN, INC.,
Patent Owner.

Case IPR2016-01132
Patent 9,248,191 B2

Before SHERIDAN K. SNEDDEN, TINA E. HULSE, and
CHRISTOPHER G. PAULRAJ, *Administrative Patent Judges*.

HULSE, *Administrative Patent Judge*.

DECISION
Institution of *Inter Partes* Review
37 C.F.R. § 42.108

I. INTRODUCTION

Mylan Pharmaceuticals Inc. (“Petitioner”) filed a Petition requesting an *inter partes* review of claims 1–27 of U.S. Patent No. 9,248,191 B2 (Ex. 1001, “the ’191 patent”). Paper 3 (“Pet.”). Allergan, Inc. (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 7 (“Prelim. Resp.”).

We have jurisdiction under 35 U.S.C. § 314, which provides that an *inter partes* review may not be instituted “unless . . . there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). Upon considering the Petition and Preliminary Response, we determine that Petitioner has established a reasonable likelihood that it would prevail in showing the unpatentability of claims 1–27. Accordingly, we institute an *inter partes* review of those claims.

A. *Related Proceedings*

The parties identify several petitions for *inter partes* review previously filed by Apotex Corp. and Apotex Inc. and challenging claims of related patents. Pet. 11; Paper 6, 2 (referring to IPR2015-01278, IPR2015-01282, IPR2015-01283, IPR2015-01284, and IPR2015-01286). All of the petitions were terminated before institution decisions were entered. Pet. 11; Paper 6, 2. The parties also identify several district court cases that may affect or be affected by a decision in this proceeding: *Allergan, Inc. v. Teva Pharms. USA, Inc., et al.*, No. 2:15-cv-01455 (E.D. Tex.); *Allergan, Inc., v.*

IPR2016-01132
Patent 9,248,191 B2

Innopharma, Inc., No. 2:15-cv-1504 (E.D. Tex.); and *Allergan, Inc. v. Famy Care, Ltd.*, No. 2:16-cv-0401 (E.D. Tex.). Pet. 11; Paper 6. 2.

Petitioner has also sought *inter partes* review for related patents in the following proceedings: Case IPR2016-01127 (U.S. Patent No. 8,685,930 B2), Cases IPR2016-01128 and IPR2016-01232 (U.S. Patent No. 8,629,111 B2), Case IPR2016-01129 (U.S. Patent No. 8,642,556 B2), Case IPR2016-01130 (U.S. Patent No. 8,633,162 B2), and Case IPR2016-01131 (U.S. Patent No. 8,648,048 B2).

B. *The '191 Patent*

The '191 patent generally relates to methods of providing therapeutic effects using cyclosporin components, and more specifically to a formulation containing cyclosporin-A (“CsA”) and castor oil emulsions for treating dry eye syndrome (i.e., keratoconjunctivitis sicca or “KCS”). Ex. 1001, 1:20–22, 1:60–67, 2:66–67. According to the specification, the prior art recognized the use of emulsions containing CsA and CsA-derivatives to treat ophthalmic conditions. *Id.* at 1:28–67. The specification notes, however, “[o]ver time, it has become apparent that cyclosporin A emulsions for ophthalmic use preferably have less than 0.2% by weight of cyclosporin A.” *Id.* at 1:66–2:1. Moreover, if reduced amounts of cyclosporin are used, reduced amounts of castor oil are needed because one of the functions of castor oil is to solubilize CsA. *Id.* at 2:1–8.

Accordingly, the specification states that “[i]t has been found that the relatively increased amounts of hydrophobic component together with relatively reduced, yet therapeutically effective, amounts of cyclosporin

component provide substantial and advantageous benefits.” *Id.* at 2:38–41. The relatively high concentration of hydrophobic component provides for a more rapid breaking down of the emulsion in the eye, which reduces vision distortion and/or facilitates the therapeutic efficacy of the composition. *Id.* at 2:45–51. Furthermore, using reduced amounts of cyclosporin component mitigates against undesirable side effects or potential drug interactions. *Id.* at 2:51–54.

The patent identifies two particular compositions that were selected for further testing, as shown below:

	Composition I wt %	Composition II wt %
Cyclosporin A	0.1	0.05
Castor Oil	1.25	1.25
Polysorbate 80	1.00	1.00
Premulen ®	0.05	0.05
Glycerine	2.20	2.20
Sodium hydroxide	qs	qs
Purified Water	qs	qs
pH	7.2-7.6	7.2-7.6
Weight Ratio of Cyclosporin A to Castor Oil	0.08	0.04

Id. at 14:26–38. Based on the results of a Phase 3 clinical study, the specification concludes that “Composition II . . . provides overall efficacy in treating dry eye disease substantially equal to that of Composition I.” *Id.* at 14:42–46. The patent indicates “[t]his is surprising for a number of reasons.” *Id.* at 14:47. According to the specification, a reduced concentration of CsA in Composition II would have been expected to result in reduced overall efficacy in treating dry eye disease. *Id.* at 14:47–50. Moreover, although the large amount of castor oil relative to the amount of

CsA in Composition II might have been expected to cause increased eye irritation, it was found to be substantially non-irritating in use. *Id.* at 14:50–55. Accordingly, the specification states that physicians can prescribe Composition II “to more patients and/or with fewer restrictions and/or with reduced risk of the occurrence of adverse events, e.g., side effects, drug interactions and the like, relative to providing Composition I.” *Id.* at 15:10–14.

C. Illustrative Claim

Petitioner challenges claims 1–27 of the ’191 patent, of which claims 1, 13, 17, and 21 are independent claims. Claim 1 is illustrative, and is reproduced below:

1. A method of treating dry eye disease, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first ophthalmic emulsion comprises cyclosporin A in an amount of about 0[.]05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight;

wherein the method is therapeutically effective in treating dry eye disease;

wherein the method provides overall efficacy substantially equal to administration of a second topical ophthalmic emulsion to a human eye in need thereof at a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of about 0.1% by weight and castor oil in an amount of about 1.25% by weight; and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.